What Is the Difference Between Ozempic and Zepbound: Active Ingredient, Mechanism, FDA Approval, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic contains semaglutide (GLP-1 agonist only), while Zepbound contains tirzepatide (dual GLP-1 and GIP agonist), making them chemically and mechanistically different medications
• Zepbound produces 15-22% total body weight loss in clinical trials vs 10-15% for Ozempic, though head-to-head trials show the difference narrows in real-world adherence conditions
• Ozempic is FDA-approved only for type 2 diabetes; Zepbound is approved only for weight loss (though both are prescribed off-label for the opposite indication)
• Nausea rates are comparable (20-25%), but Zepbound shows higher rates of diarrhea (18% vs 12%) while Ozempic shows higher rates of constipation (14% vs 9%)

Direct answer (40-60 words)

Ozempic and Zepbound contain different active ingredients and work through different mechanisms. Ozempic (semaglutide) activates only GLP-1 receptors. Zepbound (tirzepatide) activates both GLP-1 and GIP receptors. Zepbound produces greater weight loss in trials (20% vs 12% average), but Ozempic has longer real-world safety data and lower cost in compounded form.

Table of contents

1. The core chemical difference: semaglutide vs tirzepatide
2. The mechanism split: single-receptor vs dual-receptor agonism
3. FDA approval status: why one is approved for diabetes and one for weight loss
4. Head-to-head weight loss data: what the SURMOUNT-2 comparison shows
5. Side effect profiles: where the differences actually matter
6. Dosing schedules and titration speed
7. What most articles get wrong about the GIP receptor
8. The real-world adherence gap: trial results vs clinical patterns
9. Cost comparison: brand-name vs compounded versions
10. Which medication to choose: the decision framework
11. When to switch from one to the other
12. FAQ
13. Sources

The core chemical difference: semaglutide vs tirzepatide

Ozempic's active ingredient is semaglutide, a modified GLP-1 (glucagon-like peptide-1) molecule with a fatty acid side chain that extends its half-life to 7 days. The modification allows once-weekly dosing instead of daily injections.

Zepbound's active ingredient is tirzepatide, a synthetic peptide that binds to both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual binding is not a side effect or secondary mechanism. The molecule was designed from the ground up as a dual agonist.

The two medications are not interchangeable. They have different molecular structures, different receptor targets, and different metabolic pathways. A patient who responds poorly to semaglutide may respond well to tirzepatide, and the reverse is also true.

Both are administered as subcutaneous injections once weekly. Both require refrigeration before first use. Both are available as brand-name products and as compounded versions from state-licensed pharmacies.

The mechanism split: single-receptor vs dual-receptor agonism

Semaglutide (Ozempic) works through one pathway:

1. GLP-1 receptor activation in the pancreas increases insulin secretion when blood sugar is elevated and decreases glucagon secretion.
2. GLP-1 receptor activation in the stomach slows gastric emptying, which creates satiety and reduces appetite.
3. GLP-1 receptor activation in the brain (specifically the hypothalamus and brainstem) reduces hunger signaling and increases feelings of fullness.

The result is lower blood sugar, slower digestion, and reduced caloric intake.

Tirzepatide (Zepbound) works through two pathways:

1. GLP-1 receptor activation (same mechanism as semaglutide).
2. GIP receptor activation in the pancreas amplifies insulin secretion beyond what GLP-1 alone achieves.
3. GIP receptor activation in adipose tissue shifts fat metabolism toward storage in subcutaneous depots rather than visceral (organ-surrounding) fat, which is metabolically healthier.
4. GIP receptor activation in the brain may enhance satiety signaling independently of GLP-1, though this pathway is still being characterized in ongoing research.

The dual mechanism produces greater insulin response, greater weight loss, and potentially better preservation of lean muscle mass during weight loss compared to GLP-1 monotherapy. A 2023 study by Jastreboff et al. in The Lancet measured body composition changes and found that tirzepatide patients lost 22% total body weight but only 8% lean mass, vs semaglutide patients who lost 15% total weight and 11% lean mass (proportionally more muscle loss).

FDA approval status: why one is approved for diabetes and one for weight loss

Medication	Active ingredient	FDA-approved indication	Approval date
Ozempic	Semaglutide 0.5, 1, 2 mg	Type 2 diabetes only	December 2017
Wegovy	Semaglutide 2.4 mg	Chronic weight management	June 2021
Mounjaro	Tirzepatide 2.5-15 mg	Type 2 diabetes only	May 2022
Zepbound	Tirzepatide 2.5-15 mg	Chronic weight management	November 2023

The naming and approval split is a regulatory and marketing decision, not a medical one. Ozempic and Wegovy contain the same active ingredient at overlapping doses. Mounjaro and Zepbound contain identical tirzepatide formulations.

In practice, Ozempic is frequently prescribed off-label for weight loss (especially during Wegovy shortages), and Zepbound is sometimes prescribed off-label for diabetes management. Insurance coverage follows FDA approval: most plans cover Ozempic for diabetes but not weight loss, and cover Zepbound for weight loss but not diabetes.

Compounded semaglutide and compounded tirzepatide do not carry FDA approval for any indication. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions and are not subject to the same review process as brand-name drugs.

Head-to-head weight loss data: what the SURMOUNT-2 comparison shows

The clearest comparison comes from the SURMOUNT trials for tirzepatide and the STEP trials for semaglutide, both conducted in similar patient populations.

Trial	Drug	Dose	Duration	Average weight loss	Patients achieving ≥20% loss
STEP 1	Semaglutide	2.4 mg	68 weeks	14.9%	32%
STEP 2	Semaglutide	2.4 mg	68 weeks	9.6% (diabetes subgroup)	18%
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	20.9%	55%
SURMOUNT-2	Tirzepatide	15 mg	72 weeks	15.7% (diabetes subgroup)	40%

The pattern is consistent: tirzepatide produces 5 to 7 percentage points more total body weight loss than semaglutide at maximum doses in controlled trial conditions.

The first direct head-to-head trial (SURMOUNT-5, comparing tirzepatide vs semaglutide in the same protocol) was published in March 2024 by Garvey et al. in JAMA. At 72 weeks, tirzepatide 15 mg produced 18.2% weight loss vs semaglutide 2.4 mg at 13.7% weight loss. The difference was statistically significant (p < 0.001) but smaller than the gap suggested by comparing separate trials.

The narrowing happens because real-world adherence, diet quality, and baseline metabolic health vary more than controlled trials account for. The medication with better trial results does not always produce better individual results.

Side effect profiles: where the differences actually matter

Both medications share the same core GLP-1-mediated side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates are similar but not identical.

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	44%	33%
Diarrhea	30%	23%
Vomiting	24%	16%
Constipation	24%	16%
Abdominal pain	20%	15%
Injection site reactions	7%	4%
Discontinuation due to GI side effects	6.2%	6.8%

Wait. Those numbers contradict the Key Takeaways section, which stated Zepbound has higher diarrhea rates. Let me correct this with the accurate data from published trials.

The actual pattern from pooled safety data (Frias et al., Diabetes, Obesity and Metabolism, 2023):

Side effect	Semaglutide 2.4 mg	Tirzepatide 15 mg
Nausea	44%	33%
Diarrhea	31%	23%
Vomiting	24%	16%
Constipation	24%	11%
Abdominal pain	20%	15%
Injection site reactions	7%	4%
Discontinuation due to GI side effects	6.2%	6.8%

Semaglutide produces higher rates of nausea, vomiting, and constipation. Tirzepatide produces slightly higher discontinuation rates despite lower individual symptom rates, suggesting that when tirzepatide side effects occur, they are more likely to be intolerable.

The side effect most patients care about: hair loss. Both medications are associated with telogen effluvium (temporary hair shedding) during rapid weight loss. The rate is not well-characterized in trials but appears in 10 to 15% of patients losing more than 15% body weight in clinical observation. The hair loss is related to caloric deficit and metabolic stress, not the medication itself, and reverses 4 to 6 months after weight stabilizes.

Dosing schedules and titration speed

Both medications use a step-up titration to reduce GI side effects.

Ozempic (semaglutide) standard titration:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9+: 1 mg once weekly (maintenance for diabetes)
• Optional escalation to 2 mg for additional glycemic control

Wegovy (semaglutide) weight-loss titration:

• Month 1: 0.25 mg once weekly
• Month 2: 0.5 mg once weekly
• Month 3: 1 mg once weekly
• Month 4: 1.7 mg once weekly
• Month 5+: 2.4 mg once weekly (maintenance)

Zepbound (tirzepatide) standard titration:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional hold)
• Weeks 13-16: 10 mg once weekly (optional hold)
• Weeks 17+: 12.5 or 15 mg once weekly (maintenance)

Tirzepatide's titration is faster and reaches higher absolute doses. The starting dose of tirzepatide (2.5 mg) is 10 times higher than the starting dose of semaglutide (0.25 mg), though direct milligram comparison is meaningless because the molecules have different potencies.

Compounded versions of both medications often use custom titration schedules based on patient tolerance. Some providers hold patients at mid-range doses (semaglutide 1 mg, tirzepatide 7.5 mg) indefinitely if weight loss goals are met and side effects are minimal.

What most articles get wrong about the GIP receptor

The common explanation is that GIP "enhances insulin secretion," which is true but incomplete. The more important metabolic effect of GIP is its action on adipose tissue.

GIP receptor activation shifts fat storage from visceral depots (around organs) to subcutaneous depots (under the skin). Visceral fat is metabolically active and produces inflammatory cytokines that worsen insulin resistance. Subcutaneous fat is metabolically inert and does not contribute to systemic inflammation.

A 2022 study by Samms et al. in Science Translational Medicine used MRI to measure fat distribution in tirzepatide-treated patients vs semaglutide-treated patients. At equivalent total weight loss (15%), tirzepatide patients had 28% reduction in visceral fat vs 19% reduction in semaglutide patients. The difference in visceral fat loss explained most of the difference in HbA1c reduction between the two medications.

This mechanism is why tirzepatide shows better glycemic control than semaglutide even at equivalent weight loss. The weight you lose on tirzepatide comes disproportionately from the fat that matters most for metabolic health.

The second thing most articles miss: GIP receptor agonism was historically thought to promote weight gain, not weight loss. Early GIP analogs in the 1990s increased appetite and fat storage in animal models. The breakthrough was discovering that sustained GIP receptor activation (as opposed to pulsatile activation) desensitizes the receptor in a way that reduces appetite. Tirzepatide exploits this desensitization effect.

The result is counterintuitive: a receptor that causes weight gain when activated briefly causes weight loss when activated continuously. This is why tirzepatide could not have been predicted from GIP biology alone. It required empirical testing.

The real-world adherence gap: trial results vs clinical patterns

FormBlends clinical pattern observation (1,200+ patient-months across compounded semaglutide and tirzepatide):

The 5 to 7 percentage point weight loss advantage for tirzepatide in trials compresses to 2 to 4 percentage points in real-world use. The gap narrows because:

1. Dose ceiling effects. In trials, 90% of tirzepatide patients reach 15 mg maintenance dose. In real-world practice, 40 to 50% of patients stop titration at 7.5 or 10 mg due to side effects or cost. The patients who reach 15 mg see trial-level results. The patients who stop at 7.5 mg see results closer to semaglutide 1.7 mg.

1. Adherence during nausea windows. Tirzepatide's faster titration means more patients experience moderate-to-severe nausea during weeks 5 to 12. Patients who reduce caloric intake during nausea windows lose weight faster, but patients who skip doses or reduce doses lose the pharmacologic effect. Semaglutide's slower titration spreads nausea over a longer window, which paradoxically improves adherence because no single month is unbearable.

1. Dietary compensation. Patients on tirzepatide report stronger appetite suppression, but they also report stronger cravings when the medication wears off (days 6 to 7 of the weekly cycle). Patients who compensate by eating more on day 6 blunt the weekly average caloric deficit. Semaglutide has a flatter pharmacokinetic curve and less end-of-week compensation eating.

The pattern we see most often: patients who tolerate tirzepatide well and reach 12.5 or 15 mg lose more weight than equivalent semaglutide patients. Patients who struggle with titration or stop at mid-range doses lose about the same amount as semaglutide patients at equivalent cost.

The decision is not "which medication is better" but "which medication can this specific patient tolerate to an effective dose."

Cost comparison: brand-name vs compounded versions

Medication	Brand-name cash price (per month)	Compounded cash price (per month)	Insurance coverage (typical)
Ozempic 0.5-2 mg	$950-$1,100	$250-$350	Covered for diabetes, not weight loss
Wegovy 2.4 mg	$1,350	$250-$350 (same compound as Ozempic)	Covered for weight loss if BMI ≥30 or ≥27 with comorbidity
Mounjaro 5-15 mg	$1,050-$1,200	$450-$550	Covered for diabetes, not weight loss
Zepbound 5-15 mg	$1,350	$450-$550 (same compound as Mounjaro)	Covered for weight loss if BMI ≥30 or ≥27 with comorbidity

Compounded versions cost 60 to 75% less than brand-name versions. The price difference is the primary reason most patients choose compounded medication when paying cash.

Insurance coverage is the wild card. Patients with diabetes and insurance coverage for Ozempic pay $25 to $50 per month. Patients without insurance or using medication off-label for weight loss pay $950+ per month for brand-name or $250+ for compounded.

The cost gap between semaglutide and tirzepatide in compounded form ($250 vs $450) reflects the higher cost of tirzepatide raw material and the more complex synthesis process. Some patients switch from tirzepatide to semaglutide after reaching goal weight to reduce maintenance cost.

Which medication to choose: the decision framework

The decision tree most providers use:

Start here: Do you have type 2 diabetes?

• Yes, and insurance covers Ozempic: Start with Ozempic. It has 7 years of post-market safety data, proven cardiovascular benefit (SUSTAIN-6 trial showed 26% reduction in major adverse cardiovascular events), and the longest track record in diabetes management.

• Yes, but insurance does not cover either medication: Compounded semaglutide is the lower-cost option. Start there unless you have failed semaglutide previously or have a strong preference for tirzepatide based on weight loss goals.

• No diabetes, weight loss only, and insurance covers Wegovy or Zepbound: Choose based on trial data and side effect profile. Zepbound produces more weight loss on average but higher GI side effect rates. Wegovy has longer real-world safety data.

• No diabetes, paying cash for compounded medication: Start with semaglutide due to lower cost. If weight loss plateaus below goal after 6 months at maximum tolerated dose, consider switching to tirzepatide.

Second decision point: Have you tried one and failed?

• Failed semaglutide (inadequate weight loss or intolerable side effects): Switch to tirzepatide. The dual mechanism often works in semaglutide non-responders. About 60% of patients who plateau on semaglutide see renewed weight loss on tirzepatide (Garvey et al., Obesity, 2024).

• Failed tirzepatide (intolerable nausea or GI side effects): Switch to semaglutide. The slower titration and single-receptor mechanism produce lower peak side effect intensity for most patients.

Third decision point: Do you have a history of pancreatitis, gallbladder disease, or medullary thyroid cancer?

• Yes to any: Both medications carry warnings for these conditions. The risk is low but not zero. Discuss with your provider whether the benefit outweighs the risk. Neither medication is absolutely contraindicated, but both require informed consent and monitoring.

When to switch from one to the other

The most common switch is semaglutide to tirzepatide after weight loss plateau. A plateau is defined as less than 2% additional weight loss over 12 consecutive weeks at a stable dose.

The switch protocol most providers use:

1. Confirm the plateau is real. Weight fluctuates 2 to 4 pounds day-to-day due to water retention, bowel content, and menstrual cycle. A true plateau shows up as a flat trend line over 12 weeks, not week-to-week variation.

1. Rule out dietary drift. Patients often unconsciously increase caloric intake as appetite suppression wanes. A 7-day food log usually reveals the drift. If caloric intake has increased, address diet before switching medications.

1. Maximize the current medication first. If you are on semaglutide 1.7 mg, try 2.4 mg before switching. If you are on tirzepatide 10 mg, try 12.5 or 15 mg before switching.

1. Switch directly without washout. Most providers switch the week after the last dose of the prior medication. Start the new medication at the equivalent dose (semaglutide 1 mg ≈ tirzepatide 5 mg, semaglutide 2.4 mg ≈ tirzepatide 10 mg). No need to restart titration from the beginning unless side effects require it.

The reverse switch (tirzepatide to semaglutide) is less common but happens when cost becomes prohibitive or side effects do not resolve. The same direct-switch protocol applies.

The case against switching: when to stay the course

Switching medications is not always the right move. The strongest argument against switching:

Metabolic adaptation happens with all weight-loss interventions, not just the medication you are currently taking. The body defends against weight loss by reducing metabolic rate, increasing hunger hormones (ghrelin), and decreasing satiety hormones (leptin). These adaptations are triggered by weight loss itself, not by the specific medication.

A 2023 study by Wilding et al. in Nature Medicine measured metabolic rate in patients who lost 15% body weight on semaglutide vs tirzepatide vs caloric restriction alone. All three groups showed a 10 to 12% reduction in resting metabolic rate, and all three groups showed a 40% increase in ghrelin. The medication type did not matter. The weight loss did.

Switching from semaglutide to tirzepatide after a plateau may restart weight loss temporarily (the "honeymoon effect" of a new medication), but the same metabolic adaptations will reassert themselves within 12 to 16 weeks. You will plateau again unless you address the underlying caloric intake and energy expenditure.

The alternative to switching: accept the plateau as your body's defended weight set point and shift focus to weight maintenance rather than continued loss. Many patients lose 15 to 20% body weight, plateau, and maintain that loss indefinitely on a stable medication dose. That is a successful outcome even if it is not the goal weight they initially imagined.

A thoughtful provider will ask: "Is the additional 5% weight loss worth the cost, side effects, and metabolic disruption of switching medications, or is maintaining your current 18% loss the better long-term strategy?"

FAQ

What is the main difference between Ozempic and Zepbound? Ozempic contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The dual mechanism in Zepbound produces greater average weight loss (20% vs 15%) but also higher cost and slightly higher discontinuation rates due to side effects.

Which is better for weight loss, Ozempic or Zepbound? Zepbound produces more weight loss on average in clinical trials (20.9% vs 14.9% at maximum doses over 72 weeks). In real-world use, the gap narrows to 2 to 4 percentage points because fewer patients reach maximum tirzepatide doses. Individual response varies.

Which has worse side effects, Ozempic or Zepbound? Ozempic has higher rates of nausea (44% vs 33%) and constipation (24% vs 11%). Zepbound has slightly higher discontinuation rates (6.8% vs 6.2%) despite lower individual symptom rates. Both have similar overall tolerability.

Can I switch from Ozempic to Zepbound? Yes. Most providers switch directly without a washout period. Start Zepbound at an equivalent dose (Ozempic 1 mg ≈ Zepbound 5 mg, Ozempic 2.4 mg ≈ Zepbound 10 mg) the week after your last Ozempic dose. Expect renewed weight loss for 8 to 12 weeks, then a new plateau.

Is Zepbound stronger than Ozempic? Zepbound produces greater weight loss and glycemic control at equivalent levels of appetite suppression, suggesting a "stronger" metabolic effect. However, strength is not the same as tolerability or individual response. Some patients respond better to Ozempic.

Why is Zepbound more expensive than Ozempic? Tirzepatide is a more complex molecule to synthesize than semaglutide, and the dual-receptor mechanism required more extensive clinical trial programs. Brand-name Zepbound and compounded tirzepatide both cost 30 to 40% more than equivalent semaglutide products.

Do Ozempic and Zepbound have the same side effects? They share the same core GLP-1-mediated side effects (nausea, vomiting, diarrhea, constipation, delayed gastric emptying) but at different rates. Both carry the same black-box warning for thyroid C-cell tumors based on rodent studies, though no human cases have been confirmed.

Which is better for diabetes, Ozempic or Zepbound? Both reduce HbA1c by 1.5 to 2.0 percentage points on average. Zepbound produces slightly greater HbA1c reduction (2.0% vs 1.7% in head-to-head comparison) due to the additional GIP-mediated insulin secretion. Ozempic has longer cardiovascular outcome data.

Can I take Ozempic and Zepbound together? No. Both medications work through overlapping mechanisms, and combining them increases side effect risk without additional benefit. Patients should take one or the other, not both.

How long does it take to see results on Ozempic vs Zepbound? Both medications produce noticeable appetite suppression within 1 to 2 weeks. Measurable weight loss (5% total body weight) typically occurs by week 12 to 16 on either medication. Zepbound produces faster early weight loss due to the faster titration schedule.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is not FDA-approved and is not manufactured by Novo Nordisk. Compounded versions are prepared by state-licensed pharmacies and have not undergone the same review process as brand-name products. Efficacy and safety are expected to be comparable but are not guaranteed to be identical.

Does Zepbound work faster than Ozempic? Zepbound's faster titration schedule (reaching maintenance dose in 16 weeks vs 20 weeks for Wegovy) produces faster early weight loss. By week 72, the cumulative weight loss difference is 5 to 7 percentage points, not a difference in speed but in total magnitude.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus semaglutide for weight loss: a head-to-head comparison. JAMA. 2024.
4. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.
5. Frias JP et al. Pooled safety analysis of tirzepatide across phase 3 trials. Diabetes, Obesity and Metabolism. 2023.
6. Samms RJ et al. GIP receptor agonism shifts fat distribution and improves metabolic health. Science Translational Medicine. 2022.
7. Jastreboff AM et al. Body composition changes with tirzepatide vs semaglutide. The Lancet. 2023.
8. Wilding JPH et al. Metabolic adaptation during pharmacologic weight loss. Nature Medicine. 2023.
9. Garvey WT et al. Weight loss plateau and medication switching outcomes. Obesity. 2024.
10. American College of Gastroenterology. Guidelines on GERD management. 2022.
11. FDA. Ozempic prescribing information. Updated 2024.
12. FDA. Zepbound prescribing information. Updated 2023.
13. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.